Thank You to Our Sponsors:
|
|
From
the Executive
Director
|
|
|
BioSP met recently with a large pharmaceutical company where we
discussed our assistance to idea-stage technologies and companies, and our goal
of helping them to reach the next level of commercialization.
We heard that in the pharma world, there will
be increasing interest in a next level of commercialization that consists of one
or more vetted development opportunities with minimal corporate trappings.
Life sciences entrepreneurship is changing. BioSP is, too. While we continue to believe that bridging
good science and good business, and our focus on the basics at the technology transfer, scientific founder and first-time entrepreneur level are central to the
commercialization process, we're also reaching out to the many players in our sector. We're telling our story, listening to theirs, looking for ways to actively
collaborate in growing our life sciences cluster.
Karen J. Hanson, Ph.D.
|
MARK YOUR CALENDARS:
Practical Knowledge Series
Citizens Gateway Center
Plymouth Meeting, PA
March 5, 2010
Moderator:
Jeff Nicholas, Partner, Fox Rothschild LLP
Panelists:
Hal S. Broderson, MD, MBA, Managing Director, Rock Hill Ventures
Shawn M. Marcell, Vice President of Molecular
Diagnostics, Sequenom, Inc. (NASDAQ: SQNM)
J. David Owens, Angel Investor, Life Sciences, Executive, Entrepreneur
Future Practical Knowledge Series Events are scheduled for:
April 16, 2010
May 21, 2010 |
USPTO Update from Saul Ewing
|
The USPTO has very recently modified their procedures relating to patent term adjustment. Following the recent Wyeth decision, the USPTO is providing patentees with the ability to request a recalculation of their patent term adjustment without a fee or petition. Per the recent decision, an applicant is
entitled to patent term adjustment if certain actions were not taken by the USPTO during the examination and issue process within specified time frames; or if the USPTO fails to issue a patent within three years of the actual filing date of the application; or for delays due to interference, secrecy order, or successful appellate review. This procedure is available solely for alleged errors in view of the recent judicial decision. For alleged errors that fall outside the purview of the recent decision, the process remains as prescribed
by the USPTO.
The USPTO will be processing recalculation requests via a procedure that is available to a patentee whose patent issues prior to March 2, 2010, and who requests it no later than 180 days after the
issue date. Patents issuing after the March 2, 2010 date will have a patent term adjustment calculation that is
consistent with the recent decision. |
|
Saul Ewing's Anessa Abrams
and Catherine Walters were selected to present a program on Reductions in Force at the BIO
International 2010 - HR Conference in Chicago in May. This is the 2-day Conference for Bio-HR professionals that runs concurrent with BIO International 2010.
QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients
Delaware County KIZ Company, QR Pharma, Inc. (QR), a developer of novel drugs to treat Alzheimer's
disease (AD), announced that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.
Click here for more details.
QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome
QR Pharma, Inc., also announced that it was issued U.S. Patent No. 7,625,942, a
"Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that
claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer's disease (AD).
Click here for more details.
|
|
Founded in 2004,
BioStrategy Partners is a capacity-building organization providing technology
and business development services to idea-stage projects and companies in the
Greater Philadelphia region. BioSP specializes in offering
business guidance and support to first-time
entrepreneurs, scientific founders, technology
transfer officers and principal
investigators. For more information,
please visit our web site, http://www.biostrategypartners.org.
|
|
|
|
|
